Monitoring for tumor changes in people with NF1
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 3 years or older
- You have been diagnosed with NF1 (including mosaic or segmental NF1)
- You are willing to have MRI scans
- You or your parent/guardian can understand and sign a consent form
- You may have high-risk features (like a certain gene change, family history, past tumors, or large nerve tumors) or not—both groups are welcome
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether patient surveys (questionnaires) can reliably measure symptoms and pain in people with NF1 who have plexiform neurofibromas. It helps create better tools for tracking how you feel and how treatments may affect quality of life.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
This study looks for better ways to measure how much tumor activity people with neurofibromatosis type 1 (NF1) have over time. The goal is to develop “biomarkers,” which are test results that may help doctors track disease more easily.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a daily capsule called semetinib for adults with type 1 neurofibromatosis (NF1) who have at least one measurable tumor. It aims to shrink or slow tumor growth, especially for tumors that can be surgically removed.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.